Chalcone analog-based 5-reductase 1 inhibition in neurosteroidogenesis: Mechanistic insights from integrated SPR
Chentao Ding1, Yinghao Huang1, Huidan Lian2
1Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Key Laboratory of Pediatric Anesthesiology, Ministry of Education; Key Laboratory of Precision Anesthesiology of Zhejiang Province, Wenzhou Medical University; Wenzhou, Zhejiang 325027, China; Key Laboratory of Environment and Male Reproductive Medicine of Wenzhou, and Key Laboratory of Structural Malformations in Children of Zhejiang Province, Wenzhou, 325000, Zhejiang Province, China.
Abstract:
This study systematically evaluates the inhibitory effects and mechanistic actions of chalcone and 10 chalcone analogs from herbs against human and rat 5α-reductase type 1 (5α-R1), a key enzyme in dihydrotestosterone biosynthesis (for neurosteroid and androgen biosynthesis). Screening of these chemicals identified licochalcone A as the most potent inhibitor (human IC50 = 4.08 μM; rat IC50 = 4.55 μM), displaying 5.15-fold higher binding affinity than the weakest analog (4-hydroxychalcone) via surface plasmon resonance. Michaelis-Menten kinetics revealed mixed inhibition, corroborated by intersecting Lineweaver-Burk plots. SPR competitive assay showed that 4-hydroxychalcone and licochalcone A competed with NADPH in cofactor binding site of human 5α-R1. Cellular assays confirmed licochalcone A's efficacy in suppressing dihydrotestosterone production (≥1 μM in SF-126 cells). Structure-activity relationship (SAR) analysis highlighted lipophilicity (logP), steric bulk (Vol, Sterimol B5), and heteroatom count as critical determinants of potency, validated by a 3D-QSAR pharmacophore model. Molecular docking localized chalcone binding to NADPH/testosterone interfacial sites, with licochalcone A forming hydrogen bonds (Asp169, Arg232) and hydrophobic interactions. ADMET profiling indicated favorable blood-brain barrier penetration but flagged hepatotoxicity for licochalcone A. These findings position licochalcone A as a lead compound for targeting 5α-R1 in neurosteroid/androgen-related disorders.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Direct-Acting Cholinergic Agonists: Pharmacokinetics


